HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Neuromuscular

The NeurologyLive® neuromuscular disease clinical focus page offers updates and information related to the clinical care and management of individuals with neuromuscular diseases such as amyotrophic lateral sclerosis, Duchenne muscular dystrophy, cerebral palsy, and spinal muscular atrophy, as well as rare diseases. This page consists of news, podcasts, and videos about the latest FDA actions, clinical guideline updates, interviews with physicians, study and clinical trial findings, and more.

Check out some of NeurologyLive®'s featured content in the carousel below.

Post-Conference Perspectives and Updates in Neuropalliative Care: Benzi Kluger, MD, MS

November 21, 2022

Video

The president of the International Neuropalliative Care Society provided an overview of the organization’s recently concluded conference and the significance of the growth of neuropalliative care. [WATCH TIME: 6 minutes]

This Week on NeurologyLive® — November 21, 2022

November 21, 2022

Article

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: November 20, 2022

November 20, 2022

Article

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Positive Results of STK-001 in Dravet, Zavegepant Meets Primary End Points, FDA Accepts NDA of Zilucoplan for Myasthenia Gravis

November 19, 2022

Video

Neurology News Network for the week ending November 19, 2022. [WATCH TIME: 3 minutes]

NeurologyLive® Friday 5 — November 18, 2022

November 18, 2022

Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 18, 2022.

Rituximab Significantly Lessens Myasthenia Gravis Manifestations, Rescue Treatments Needed

November 18, 2022

Article

Compared with placebo, a greater proportion of patients on rituximab met the primary end point of minimal disease manifestations at 16 weeks, and demonstrated favorable results on several secondary end points.

Episode 77: A New Era of Myasthenia Gravis Treatment

November 18, 2022

Podcast

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with George Small, MD. [LISTEN TIME: 33 minutes]

Clinical Application of Transcranial Direct Current Stimulation for Poststroke Symptoms: Wayne Feng, MD, FAHA

November 16, 2022

Video

The division chief of stroke and vascular neurology at Duke Health discussed advantages and capabilities, as well as limitations and barriers of transcranial direct current stimulation to treat poststroke symptoms. [WATCH TIME: 4 minutes]

NeuroVoices: Timothy Miller, MD, PhD, on the Impact of Tofersen, Antisense Therapeutics in ALS

November 16, 2022

Article

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.

FDA Accepts NDA for Myasthenia Gravis Treatment Zilucoplan

November 14, 2022

Article

Zilucoplan, a complement C5 inhibitor, demonstrated a safe and tolerable profile, while meeting its primary and secondary end points in the phase 3 RAISE trial—the basis for its new drug application.